Neurogene Inc.
General ticker "NGNE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $383.7M (TTM average)
Neurogene Inc. follows the US Stock Market performance with the rate: 48.5%.
Estimated limits based on current volatility of 3.7%: low 20.11$, high 21.66$
Factors to consider:
- Total employees count: 91 as of 2023
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [12.59$, 34.52$]
- 2025-12-31 to 2026-12-31 estimated range: [9.49$, 26.41$]
Short-term NGNE quotes
Long-term NGNE plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.93MM |
| Operating Expenses | $56.52MM | $55.58MM | $83.53MM |
| Operating Income | $-56.52MM | $-55.58MM | $-82.61MM |
| Non-Operating Income | $1.33MM | $19.27MM | $7.46MM |
| Interest Expense | $0.00MM | $0.01MM | $0.01MM |
| R&D Expense | $47.51MM | $44.39MM | $60.92MM |
| Income(Loss) | $-55.19MM | $-36.32MM | $-75.14MM |
| Profit(Loss)* | $-55.19MM | $-36.32MM | $-75.14MM |
| Stockholders Equity | $98.63MM | $186.02MM | $310.38MM |
| Assets | $109.27MM | $222.57MM | $335.73MM |
| Operating Cash Flow | $-52.82MM | $-51.42MM | $-70.60MM |
| Capital expenditure | $2.23MM | $0.32MM | $0.81MM |
| Investing Cash Flow | $-2.23MM | $25.64MM | $-125.26MM |
| Financing Cash Flow | $66.53MM | $92.48MM | $184.07MM |
| Earnings Per Share** | $-4.30 | $-2.83 | $-4.28 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.